Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Javle, M. [1 ]
Fogelman, D. [1 ]
Kaseb, A. [1 ]
Varadhachary, G. [1 ]
Wolff, R. [1 ]
Abbruzzese, J. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72262-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：104 / 104
页数：1
相关论文
共 50 条
  • [41] Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer
    Papewalis, C.
    Wuttke, M.
    Schinner, S.
    Willenberg, H. S.
    Baran, A. M.
    Scherbaum, W. A.
    Schott, M.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 752 - 756
  • [42] Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells
    I Tsaur
    J Makarević
    E Juengel
    M Gasser
    A-M Waaga-Gasser
    M Kurosch
    M Reiter
    S Wedel
    G Bartsch
    A Haferkamp
    C Wiesner
    R A Blaheta
    British Journal of Cancer, 2012, 107 : 847 - 855
  • [43] A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination with Capecitabine for Metastatic Breast Cancer.
    Chen, C. S.
    Chen, M. M.
    Imaoka, R. T.
    Svahn, T.
    Guardino, A. E.
    CANCER RESEARCH, 2009, 69 (24) : 860S - 860S
  • [44] Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Chen, L.
    Shiah, H. S.
    Chen, C. Y.
    Lin, Y. J.
    Lin, P. W.
    Su, W. C.
    Chang, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Su Jin Lee
    Jongtae Lee
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Young Suk Park
    Ho Yeong Lim
    Kyoung-Mee Kim
    In-Gu Do
    Sin-Ho Jung
    Dong-Seok Yim
    Won Ki Kang
    Investigational New Drugs, 2013, 31 : 1580 - 1586
  • [46] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Lee, Su Jin
    Lee, Jongtae
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kim, Kyoung-Mee
    Do, In-Gu
    Jung, Sin-Ho
    Yim, Dong-Seok
    Kang, Won Ki
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1580 - 1586
  • [47] Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
    Ghobrial, Irene M.
    Gertz, Morie A.
    LaPlant, Betsy
    Camoriano, John Kelly
    Hayman, Suzanne R.
    Lacy, Martha
    Chuma, Stacey
    Harris, Brianna
    Boswell, Erica
    Banwait, Ranjit
    Sheehy, Patricia
    Ansell, Stephen Maxted
    DeAngelo, Daniel J.
    Dispenzieri, Angela
    Bergsagel, Leif
    Reeder, Craig B.
    Anderson, Kenneth Carl
    Richardson, Paul Gerard Guy
    Treon, Steven P.
    Witzig, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
  • [49] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Suee Lee
    Hyuk Chan Kwon
    Gyeong Won Lee
    Seil Go
    Myoung Hee Kang
    Young Joo Cha
    Jung Hun Kang
    Investigational New Drugs, 2012, 30 : 2371 - 2376
  • [50] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
12345